New combo therapy targets deadly brain cancer recurrence
NCT ID NCT03961971
First seen Nov 01, 2025 · Last updated Jun 11, 2026 · Updated 23 times
Summary
This early-stage trial tests a new treatment for glioblastoma that has come back after initial therapy. It combines precise radiation (stereotactic radiosurgery) with two immunotherapy drugs that help the immune system attack cancer cells. The study involves 16 adults and primarily aims to check safety and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA MULTIFORME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287, United States
-
Stanford University
Stanford, California, 94305, United States
Conditions
Explore the condition pages connected to this study.